The Breast xxx (2015) 1
Contents lists available at ScienceDirect
The Breast journal homepage: www.elsevier.com/brst
Letter to the editor
Treatment for patients with Her2-Positive breast cancer may have ethnic-related adverse events
Keywords: Her2-positive breast cancer Adverse events Ethnicity
in patients from other region. In addition, Asian patients receiving docetaxel have a higher incidence of chemotherapy-related grade3 hematologic toxicity than other races, due to a low level of CYP3A4 enzyme, which is positively correlated with docetaxel clearance. It is the ethnicity differences that should be noted. And further investigations are needed to adapt a suitable treatment protocol for patients with different ethnicity.
References To the Editor I commend Cynthia Villarreal-Garza et al. [1] for their excellent article that evaluate the prognosis of Her2-positive breast cancer in Hispanic patients treated with trastuzumab-based neoadjuvant chemotherapy. The authors proposed a translucent fact that ethnicity is not an relevant factor that result in poor prognosis. In addition, a latest finding should be further emphasized. In the phase III CLEOPATRA trial conducted by Sandra M. Swain et al. [2], some adverse events are proved to be ethnic-related. In this trial, Patients were enrolled indifferent regions. Data shows that patients with HER2-positive metastatic breast cancer from Asia experienced more toxicities with pertuzumab than patients from other regions. The experimental arms with pertuzumab have a incidence of 26% in Asia patients with febrile neutropenia, which can also result in higher incidence of mucosal inflammation and diarrhea. However, the incidence was 10% or less in either arm
[1] Villarreal-Garza C, Soto-Perez-de-Celis E, Sifuentes E, Ruano S, BaezRevueltas B, Lara-Medina F, et al. Outcomes of Hispanic women with lymphnode positive, HER2 positive breast cancer treated with neoadjuvantchemotherapy and trastuzumab in Mexico. Breast 2015 Jun;24(3):218e23. [2] Swain SM, Im YH, Im SA, Chan V, Miles D, Knott A, et al. Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermalgrowth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. Oncologist 2014 Jul;19(7):693e701.
Xiaoshen Zhang* Tongji University Cancer Institute, Tongji University School of Medicine, Shanghai 200092, China *
Tel.: þ86 15221517298. E-mail address: [email protected]. 3 April 2015 Available online xxx
http://dx.doi.org/10.1016/j.breast.2015.05.008 0960-9776/© 2015 Elsevier Ltd. All rights reserved.
Please cite this article in press as: Zhang XTreatment for patients with Her2-Positive breast cancer may have ethnic-related adverse events, The Breast (2015), http://dx.doi.org/10.1016/j.breast.2015.05.008
Contents lists available at ScienceDirect
The Breast journal homepage: www.elsevier.com/brst
Letter to the editor
Treatment for patients with Her2-Positive breast cancer may have ethnic-related adverse events
Keywords: Her2-positive breast cancer Adverse events Ethnicity
in patients from other region. In addition, Asian patients receiving docetaxel have a higher incidence of chemotherapy-related grade3 hematologic toxicity than other races, due to a low level of CYP3A4 enzyme, which is positively correlated with docetaxel clearance. It is the ethnicity differences that should be noted. And further investigations are needed to adapt a suitable treatment protocol for patients with different ethnicity.
References To the Editor I commend Cynthia Villarreal-Garza et al. [1] for their excellent article that evaluate the prognosis of Her2-positive breast cancer in Hispanic patients treated with trastuzumab-based neoadjuvant chemotherapy. The authors proposed a translucent fact that ethnicity is not an relevant factor that result in poor prognosis. In addition, a latest finding should be further emphasized. In the phase III CLEOPATRA trial conducted by Sandra M. Swain et al. [2], some adverse events are proved to be ethnic-related. In this trial, Patients were enrolled indifferent regions. Data shows that patients with HER2-positive metastatic breast cancer from Asia experienced more toxicities with pertuzumab than patients from other regions. The experimental arms with pertuzumab have a incidence of 26% in Asia patients with febrile neutropenia, which can also result in higher incidence of mucosal inflammation and diarrhea. However, the incidence was 10% or less in either arm
[1] Villarreal-Garza C, Soto-Perez-de-Celis E, Sifuentes E, Ruano S, BaezRevueltas B, Lara-Medina F, et al. Outcomes of Hispanic women with lymphnode positive, HER2 positive breast cancer treated with neoadjuvantchemotherapy and trastuzumab in Mexico. Breast 2015 Jun;24(3):218e23. [2] Swain SM, Im YH, Im SA, Chan V, Miles D, Knott A, et al. Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermalgrowth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. Oncologist 2014 Jul;19(7):693e701.
Xiaoshen Zhang* Tongji University Cancer Institute, Tongji University School of Medicine, Shanghai 200092, China *
Tel.: þ86 15221517298. E-mail address: [email protected]. 3 April 2015 Available online xxx
http://dx.doi.org/10.1016/j.breast.2015.05.008 0960-9776/© 2015 Elsevier Ltd. All rights reserved.
Please cite this article in press as: Zhang XTreatment for patients with Her2-Positive breast cancer may have ethnic-related adverse events, The Breast (2015), http://dx.doi.org/10.1016/j.breast.2015.05.008
